Alembic's ANDA, approved liposomal doxorubicin matches Doxil, treating cancers with $29M market potential. The company now has 224 USFDA approvals, including 201 final and 23 tentative.

• Treats ovarian cancer, AIDS, related Kaposi's sarcoma, and multiple myeloma with strong demand.
• Vertically integrated R&D firm with global generic drug manufacturing and marketing.
• Facilities approved by the USFDA and other developed nations' agencies for quality assurance.